Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Post-traumatic stress disorder affects approximately 13 million Americans at any given time, and an estimated one-third of patients do not respond adequately to existing treatments — including first-line medications like sertraline and paroxetine, and evidence-based psychotherapies like prolonged exposure and cognitive processing therapy. For these individuals, PTSD becomes a chronic condition that reshapes every aspect of daily life. A Phase 3 clinical trial published in Nature Medicine tested whether MDMA, combined with structured psychotherapy, could move the needle for severe cases.
Mitchell JM and colleagues conducted a randomized, double-blind, placebo-controlled Phase 3 study involving 90 participants with severe PTSD. Participants had a mean Clinician-Administered PTSD Scale (CAPS-5) score of approximately 44 at baseline, indicating severe symptomatology, and many had experienced their index trauma more than a decade prior. The study included a diverse sample, with participants who had comorbid conditions including dissociative subtype PTSD, depression, and histories of alcohol and substance use disorders.
Participants received three sessions of MDMA-assisted therapy (or placebo with therapy) spaced approximately one month apart. Each MDMA session was embedded in a course of non-directive psychotherapy that included three preparatory sessions and nine integration sessions. The MDMA dose was 80-120 mg per session.
The results were striking. At the primary endpoint (18 weeks after baseline), the MDMA group showed a mean CAPS-5 reduction of 24.4 points compared to 13.9 points in the placebo group — a statistically and clinically significant difference. Of the MDMA group, 67 percent no longer met diagnostic criteria for PTSD, compared to 32 percent of the placebo group. Remission rates were also markedly different: 33 percent in the MDMA group versus 5 percent in the placebo group achieved a CAPS-5 score below 12, indicating minimal or no symptoms.
The treatment was generally well-tolerated. The most common side effects during MDMA sessions included muscle tightness, decreased appetite, nausea, and increased perspiration. No serious cardiac events occurred despite MDMA's known sympathomimetic properties. Suicidality did not increase in the MDMA group.
These results are among the most robust ever reported for any PTSD treatment, pharmacological or psychotherapeutic. The effect size (Cohen's d = 0.91) exceeded what has been observed for SSRIs, prazosin, or standard trauma-focused psychotherapy in treatment-resistant populations. The fact that the sample included patients with severe, chronic PTSD and significant comorbidity makes the findings more clinically relevant, not less — this is the population that most needs new options.
However, the path from trial to treatment has been complex. The FDA issued a Complete Response Letter for MDMA-assisted therapy in 2024, requesting additional data rather than granting approval. Methodological questions about the adequacy of blinding (MDMA's subjective effects make placebo control challenging) and concerns about some of the data integrity have been part of the regulatory discussion. As of now, MDMA-assisted therapy is not FDA-approved and remains available only through clinical trials and expanded access programs.
For clinicians, the Mitchell et al. trial demonstrates both the potential of combining pharmacological and psychotherapeutic approaches and the complexity of developing psychedelic-assisted therapies within existing regulatory frameworks.
If you or someone you know is living with PTSD that has not responded to standard treatment, the MDMA research offers genuine grounds for cautious optimism about the future of treatment. However, MDMA-assisted therapy is not currently available outside of clinical trials and expanded access.
In the interim, ketamine therapy — which can be prescribed off-label by physicians — has shown preliminary evidence of benefit for PTSD symptoms, particularly when comorbid depression is present. Ketamine's rapid-acting properties may help stabilize symptoms enough to engage more fully in trauma-focused psychotherapy, creating a bridge while newer psychedelic-assisted treatments move through the regulatory process.
A rigorous Phase 3 trial found that MDMA-assisted therapy produced large, clinically meaningful reductions in severe PTSD symptoms, with 67 percent of participants no longer meeting diagnostic criteria after three sessions. While regulatory approval has not yet been granted, this study represents a milestone in psychedelic-assisted treatment research.
Reference: Mitchell JM, et al. "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study." Nature Medicine. 2021;27:1025-1033. DOI: 10.1038/s41591-021-01336-3.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
